| 臺大學術典藏 |
2021-08-20T08:00:38Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:39Z |
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
|
BIN-CHI LIAO; Griesing S.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
BIN-CHI LIAO; Bai Y.-Y.; Lee J.-H.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:40Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; BIN-CHI LIAO; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis
|
Guo J.-C.; Chang C.-C.; Yang C.-Y.; BIN-CHI LIAO; Liau J.-Y.; Chang C.-H.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:41Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
BIN-CHI LIAO; Lin C.-C.; Lee J.-H.; Yang J.C.-H. |
